Dynamics of Quality of Life Indices in Case of Metabolic Syndrome in Patients with Paranoid Schizophrenia on the Background of Atypical Neuroleptic Agents Application and Improvement of Comorbidity

Abstract

The objective of the research was to study the features of quality of life dynamics depending on clinical and psychopathological symptoms in patients with paranoid schizophrenia asso ciated with metabolic syndrome on the background of long-term neuroleptic therapy and to study the eff ectiveness of concomitant corrective therapy. 140 patients with paranoid schizophrenia (F20.0) were examined and divided into three groups. Group I included 40 patients who received haloperidol at an ave rage daily dose of 4.6 ± 1.3 mg/day, Group II consisted of 40 patients who received risperidone (3.7 ± 1.8 mg/day), Group III included 40 patients who received quetiapine (413 ± 116 mg/day). Half of the patients in each of the presented groups continued to receive neuroleptic therapy according to the above mentioned regimen, and the other half of the patients received metformin hydro chloride at a dose of 500 mg/day in addition to the standard therapy. The cont rol group consisted of 20 patients diag nosed with "paranoid schizophrenia, remission", without metabolic syndrome signs, who had not received neuroleptics for the past six months. The Positive and Negative Syndrome Scale (PANSS) and the Medical Outcomes Study 36-Item Short-Form Health Status Questionnaire (SF-36) were used to study the patients’ mental health in detail. In this research, we monitored the impact of comorbidity on quality of life indices in the patients with long-lasting treatment of schizophrenia by neuroleptic agents, and noted that concomitant corrective therapy was appropriate in terms of compliance increase and quality of life indices improvement in the studied category of patients. Keywords: paranoid schizophrenia, metabolic syndrome, atypical neuroleptic agents, quality of life